JP4873877B2 - Method for producing sodium alginate-containing tablet and tablet obtained by the production method - Google Patents

Method for producing sodium alginate-containing tablet and tablet obtained by the production method Download PDF

Info

Publication number
JP4873877B2
JP4873877B2 JP2005100266A JP2005100266A JP4873877B2 JP 4873877 B2 JP4873877 B2 JP 4873877B2 JP 2005100266 A JP2005100266 A JP 2005100266A JP 2005100266 A JP2005100266 A JP 2005100266A JP 4873877 B2 JP4873877 B2 JP 4873877B2
Authority
JP
Japan
Prior art keywords
oil
tablet
sodium alginate
tablets
tableting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2005100266A
Other languages
Japanese (ja)
Other versions
JP2006273826A (en
Inventor
秀晃 北郡
尚子 原田
邦英 高橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kobayashi Pharmaceutical Co Ltd
Original Assignee
Kobayashi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobayashi Pharmaceutical Co Ltd filed Critical Kobayashi Pharmaceutical Co Ltd
Priority to JP2005100266A priority Critical patent/JP4873877B2/en
Priority to PCT/JP2006/306762 priority patent/WO2006106889A1/en
Publication of JP2006273826A publication Critical patent/JP2006273826A/en
Application granted granted Critical
Publication of JP4873877B2 publication Critical patent/JP4873877B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734Alginic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives

Description

本発明は、アルギン酸ナトリウム含有錠剤の製造方法及び該製造方法により得られる錠剤、さらに精油を含有する該錠剤に関する。   The present invention relates to a method for producing a tablet containing sodium alginate, a tablet obtained by the production method, and the tablet containing essential oil.

近年、食物繊維は、血圧の上昇の抑制、コレステロール値上昇抑制、血糖値上昇抑制、整腸、便秘抑制などの作用を有する機能性食品として注目されている。このため、食物繊維を配合した食品が数多く市販されている。食物繊維は人の消化酵素によって加水分解されない難消化性の多糖、リグニンなどをいい、水に対する溶解性によって、水溶性食物繊維と不溶性食物繊維とに大別される。このため、食物繊維をサプリメント等の機能性食品で好まれる剤型(特に錠剤)に成型することが求められている。   In recent years, dietary fiber has attracted attention as a functional food having actions such as suppression of blood pressure increase, cholesterol level increase suppression, blood sugar level increase suppression, bowel regulation, and constipation suppression. For this reason, many foods containing dietary fiber are commercially available. Dietary fiber refers to indigestible polysaccharides such as lignin that are not hydrolyzed by human digestive enzymes, and is roughly classified into water-soluble dietary fiber and insoluble dietary fiber according to solubility in water. For this reason, it is calculated | required that a dietary fiber is shape | molded in the dosage form (especially tablet) liked with functional foods, such as a supplement.

しかしながら、食物繊維粉末は粘着性に乏しいため、結合剤、賦形剤を配合することなく、湿式造粒法等の方法により錠剤を調製しようとしてもそれ自身の結合性が低いため調製が困難であり、食物繊維のみの錠剤は知られていなかった。このため、食物繊維含有錠剤の製造においては、食物繊維を結合させるための結合剤や賦形剤などの結合成分を配合することに重点がおかれていた。例えば、滑沢剤として卵殻粉末を使用し、キトサンを錠剤化する技術(例えば、特許文献1参照)、海草類粉末、笹類粉末に水分とキシロオリゴ糖を配合して造粒し、造粒物を乾燥後、打錠し錠剤化する技術(例えば、特許文献2)などが知られている。しかしながら、結合成分を配合することによって単位量あたりの食物繊維含有量が減少し、所定量の食物繊維を摂取するためには、必然的に、多量の錠剤を摂取する必要があった。また、水分を配合することによって、その後に乾燥工程が必要となったり、食物繊維が膨脹し乾燥しても嵩高いままになる。このため、錠剤単位量あたりの食物繊維含有量、工程数、コストなどの面から、結合成分や水分の配合は極力抑制することが望まれる。   However, dietary fiber powder has poor adhesiveness, so it is difficult to prepare tablets even when trying to prepare tablets by a wet granulation method without blending binders and excipients. There were no known dietary fiber tablets. For this reason, in the production of dietary fiber-containing tablets, emphasis has been placed on blending binding components such as binders and excipients for binding dietary fiber. For example, using eggshell powder as a lubricant and tableting chitosan (see, for example, Patent Document 1), seaweed powder, moss powder and water and xylooligosaccharides are mixed and granulated. A technique of tableting and tableting after drying (for example, Patent Document 2) is known. However, the dietary fiber content per unit amount is reduced by blending the binding component, and in order to take a predetermined amount of dietary fiber, it is necessary to take a large amount of tablets. In addition, by blending water, a drying step is necessary thereafter, or the dietary fiber expands and dries and remains bulky. For this reason, in view of dietary fiber content per unit amount of tablet, the number of steps, cost, etc., it is desired to suppress the blending of binding components and moisture as much as possible.

一方、アロマ製剤(主として天然精油)の塗擦、散布、吸入、咀嚼などにより、覚醒、睡眠、食欲抑制、食欲促進、嫌煙、制吐、抗失神、催淫性、無性欲化等の効果を得られるとして、アロマテラピーが最近注目されている。しかしながら、精油含有錠剤を製造しようとすると、精油成分は油性であるため、通常の賦形剤、滑沢剤にはなじみにくく、油浮きや精油の安定性などの問題が生じ錠剤化が困難であった。
特開平10−225285号公報 特開2002−65213号公報
On the other hand, effects such as awakening, sleep, appetite suppression, appetite promotion, smoke suppression, antiemesis, anti-fainting, aphrodisiac, asexuality, etc. can be obtained by applying, spraying, inhaling, chewing, etc. of aroma preparations (mainly natural essential oils) As aromatherapy has recently been attracting attention. However, when trying to produce essential oil-containing tablets, the essential oil component is oily, so it is difficult to fit into ordinary excipients and lubricants, causing problems such as oil floatation and essential oil stability, making tableting difficult. there were.
JP-A-10-225285 JP 2002-65213 A

したがって、本発明は、結合成分の配合を極力抑制した食物繊維含有錠剤、精油を含有する錠剤、これら錠剤の製造方法の提供を目的とする。   Accordingly, an object of the present invention is to provide a dietary fiber-containing tablet in which the combination of binding components is suppressed as much as possible, a tablet containing essential oil, and a method for producing these tablets.

本発明者らは、上記従来技術の問題点に鑑み鋭意検討を重ねた結果、それ自身では打錠による錠剤化が困難であると認識されていた食物繊維であるが、アルギン酸ナトリウムを用いて打錠すると錠剤化が可能であること、さらに、賦形剤や滑沢剤と相性の悪い精油が、アルギン酸ナトリウムを打錠して得られる錠剤に安定的に保持されることを見出し本発明を完成させた。   As a result of intensive studies in view of the above-mentioned problems of the prior art, the present inventors have found that it is a dietary fiber that has been recognized to be difficult to be tableted by tableting. Completion of the present invention by finding that tablets can be tableted and that essential oils that are incompatible with excipients and lubricants are stably held in tablets obtained by tableting sodium alginate I let you.

すなわち、本発明は、下記の製造方法及び錠剤を提供するものである。
項1.アルギン酸ナトリウム粉末を打錠するアルギン酸ナトリウム含有錠剤の製造方法。
項2.アルギン酸ナトリウム粉末の平均粒子径が40μm〜180μmである項1に記載の製造方法。
項3.アルギン酸ナトリウム粉末を打錠して得られる錠剤に精油をしみこませることを特徴とする項1又は2に記載の錠剤の製造方法。
項4.精油がパチュリー油、ジャスミン油、サンダルウッド油、バジル油、メリッサ油、ジュニパー油、ラベンダー油及びクローブ油からなる群から選択される少なくとも1種である項3に記載の製造方法。
項5.精油配合量がアルギン酸ナトリウム100重量部に対し0.01〜30重量部である、項3又は4に記載の製造方法。
項6.項1〜5のいずれかの製造方法により得られるアルギン酸ナトリウム含有錠剤。
項7.アルギン酸ナトリウムの含有量が30〜100重量%である項6に記載の錠剤。
本発明はさらに下記の錠剤も包含しうる。
項8.項1〜6のいずれかに記載の錠剤を含有する食品組成物。
項9.項1〜6のいずれかに記載の錠剤を含有する医薬組成物。
That is, the present invention provides the following production method and tablet.
Item 1. A method for producing a sodium alginate-containing tablet for tableting sodium alginate powder.
Item 2. Item 2. The production method according to Item 1, wherein the sodium alginate powder has an average particle size of 40 µm to 180 µm.
Item 3. Item 3. The method for producing a tablet according to Item 1 or 2, wherein essential oil is impregnated into a tablet obtained by tableting sodium alginate powder.
Item 4. Item 4. The method according to Item 3, wherein the essential oil is at least one selected from the group consisting of patchouli oil, jasmine oil, sandalwood oil, basil oil, melissa oil, juniper oil, lavender oil, and clove oil.
Item 5. The manufacturing method of claim | item 3 or 4 whose essential oil compounding quantity is 0.01-30 weight part with respect to 100 weight part of sodium alginate.
Item 6. Item 6. A sodium alginate-containing tablet obtained by the production method according to any one of Items 1 to 5.
Item 7. Item 7. The tablet according to Item 6, wherein the content of sodium alginate is 30 to 100% by weight.
The present invention can further include the following tablets.
Item 8. Item 7. A food composition comprising the tablet according to any one of Items 1 to 6.
Item 9. Item 7. A pharmaceutical composition comprising the tablet according to any one of Items 1 to 6.

本発明の製造方法は、アルギン酸ナトリウム粉末を打錠することによりアルギン酸ナトリウム含有錠剤を製造することを特徴とする。なお、本明細書において、アルギン酸ナトリウム粉末を打錠することにより得られる錠剤を「素錠」と称することがある。素錠には、精油をしみこませたり、コーティング、糖衣などを施すことによって様々な形態の錠剤、コーティング錠、糖衣錠、食品組成物、医薬組成物とすることが可能である。   The production method of the present invention is characterized in that sodium alginate-containing tablets are produced by tableting sodium alginate powder. In the present specification, a tablet obtained by tableting sodium alginate powder may be referred to as a “plain tablet”. The uncoated tablets can be made into various forms of tablets, coated tablets, dragees, food compositions, and pharmaceutical compositions by impregnating essential oils, coating, sugar coating, and the like.

アルギン酸ナトリウムは公知物質であり、食品添加物としても知られ、例えば海草類から公知の方法で抽出することにより製造できる。また、アルギン酸ナトリウムは市販されており、株式会社キミカ製、共成製薬株式会社製のものなどが知られている。本発明において使用されるアルギン酸ナトリウムはこれらも使用できるが、これらに限定されず、公知のアルギン酸ナトリウムを広く使用できる。本製造方法においてアルギン酸ナトリウムの分子量(重量平均)は、錠剤化できる範囲内であれば特に制限されないが、通常2万〜12万、好ましくは4万〜7万である。また、アルギン酸ナトリウム粉末の平均粒子径も特に制限されるものではないが、通常10μm〜850μm、好ましくは40μm〜180μmである。   Sodium alginate is a known substance, also known as a food additive, and can be produced, for example, by extraction from seaweed by a known method. Sodium alginate is commercially available, and those manufactured by Kimika Co., Ltd. and Kyosei Pharmaceutical Co., Ltd. are known. Although these can also be used for the sodium alginate used in this invention, it is not limited to these, The well-known sodium alginate can be used widely. In this production method, the molecular weight (weight average) of sodium alginate is not particularly limited as long as it is within the range that can be tableted, but is usually 20,000 to 120,000, preferably 40,000 to 70,000. The average particle size of the sodium alginate powder is not particularly limited, but is usually 10 μm to 850 μm, preferably 40 μm to 180 μm.

次に、本発明の製造方法ではアルギン酸ナトリウム粉末を打錠(直接粉末圧縮、直打)する。食物繊維は打錠によって成型することが困難であると認識されていたが、アルギン酸ナトリウムではそれが可能である。打錠することにより、顆粒物を圧縮する乾式顆粒圧縮法や湿式顆粒圧縮法(間接圧縮法)と比較して工程数を省略できる。打錠にあたっては公知の打錠方法を広く採用することができる。例えば、1又はそれ以上のきね、うすがターンテーブルに取り付けられ、ターンテーブルの1回転により、取り付けられているきね、うすの組数だけ錠剤ができるロータリー(回転式)打錠機、傾斜ローラ型打錠機などを採用することができる。打錠圧は、錠剤の形状や大きさ、アルギン酸ナトリウムの粒径、打錠機の種類などに応じて適宜設定することができるが、通常0.5トン(ton)/cm〜3トン(ton)/cm、好ましくは1トン(ton)/cm〜2トン(ton)/cmである。 Next, in the production method of the present invention, the sodium alginate powder is compressed (direct powder compression, direct compression). Dietary fiber has been recognized as difficult to mold by tableting, but sodium alginate is possible. By tableting, the number of steps can be omitted as compared with a dry granule compression method or a wet granule compression method (indirect compression method) for compressing granules. For tableting, known tableting methods can be widely adopted. For example, a rotary (rotary) tableting machine, in which one or more knives / lights are attached to a turntable, and a single turn of the turntable can produce tablets as many as the number of knives / lights attached. A roller type tableting machine or the like can be employed. The tableting pressure can be appropriately set according to the shape and size of the tablet, the particle size of sodium alginate, the type of tableting machine, etc., but usually 0.5 ton / cm 2 to 3 ton ( ton) / cm 2 , preferably 1 ton / cm 2 to 2 ton / cm 2 .

なお、本発明の製造方法では、打錠性を損なわない範囲であれば、アルギン酸ナトリウム粉末に、賦形剤(乳糖、白糖、D−マンニトール、でんぷん、リン酸水素カルシウムなど)、崩壊剤(でんぷん、カルメロースカルシウム、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウムなど)、滑沢剤(ステアリン酸マグネシウム、精製タルク、ステアリン酸、ショ糖脂肪酸エステルなど)、結合剤(結晶セルロース、でんぷんのり液、ヒドロキシプロピルセルロース、カルメロース、ポリビニルアルコール、ポリビニルピロリドン、アラビアゴム、ゼラチン、トラガント、水、エタノールなど)、その他の適当な添加剤を混合し打錠することもできる。打錠のための原料粉末中のアルギン酸ナトリウム粉末含有量は、通常90重量%以上、好ましくは95重量%以上である。   In the production method of the present invention, as long as tabletability is not impaired, sodium alginate powder, excipients (lactose, sucrose, D-mannitol, starch, calcium hydrogen phosphate, etc.), disintegrant (starch) , Carmellose calcium, croscarmellose sodium, sodium carboxymethyl starch), lubricant (magnesium stearate, purified talc, stearic acid, sucrose fatty acid ester, etc.), binder (crystalline cellulose, starch paste, hydroxypropyl) Cellulose, carmellose, polyvinyl alcohol, polyvinyl pyrrolidone, gum arabic, gelatin, tragacanth, water, ethanol, etc.) and other suitable additives can be mixed and tableted. The content of sodium alginate powder in the raw material powder for tableting is usually 90% by weight or more, preferably 95% by weight or more.

このようにして得られるアルギン酸ナトリウム含有錠剤(素錠)は、それ自身が食物繊維錠として有用である。このため、健康食品、機能性食品、特定保健用食品、病者用食品等としても有用である。錠剤の形状、大きさは、服用に適した形状、大きさであれば特に限定されず、例えば円型、楕円型、角型などで重量が100〜800mg、大きさが6〜12mmφであり、好ましくは、円型で重量が400〜600mgであり、大きさが7〜10mmφである。   The sodium alginate-containing tablet (plain tablet) thus obtained is useful as a dietary fiber tablet itself. For this reason, it is also useful as a health food, functional food, food for specified health use, food for the sick, and the like. The shape and size of the tablet are not particularly limited as long as it is a shape and size suitable for taking, for example, a circular shape, an elliptical shape, a square shape, and the weight is 100 to 800 mg, and the size is 6 to 12 mmφ. Preferably, it is circular and has a weight of 400 to 600 mg and a size of 7 to 10 mmφ.

前記のように、素錠には、精油をしみこませたり、コーティング、糖衣などを施すことによって様々な形態の錠剤、コーティング錠、糖衣錠、食品組成物、医薬組成物とすることが可能である。これらの形態におけるアルギン酸ナトリウム含有量は通常、30〜100重量%、好ましくは50〜100重量%、より好ましくは80〜100重量%、よりいっそう好ましくは90〜100重量%である。単位量あたりのアルギン酸ナトリウム量を大きくすることが求められる場合には上記の範囲のうち、狭い範囲を選択することができる。   As described above, the uncoated tablets can be made into various forms of tablets, coated tablets, dragees, food compositions, and pharmaceutical compositions by impregnating essential oils, coating, sugar coating, and the like. The sodium alginate content in these forms is usually 30-100% by weight, preferably 50-100% by weight, more preferably 80-100% by weight, and even more preferably 90-100% by weight. When it is required to increase the amount of sodium alginate per unit amount, a narrow range can be selected from the above ranges.

上記のアルギン酸ナトリウム含有錠剤(素錠)は精油との相性が良く、この素錠に精油をしみこませることによって、精油が油浮きせず、安定に精油が保持された錠剤を得ることができる。精油をしみこませる方法としては、素錠に精油を滴下する方法、素錠に精油を噴霧する方法、素錠に精油を含浸する方法、素錠と精油に対して減圧・昇圧を組み合わせて含浸する方法、中空状膨化処理した素錠の少なくとも内部表面に精油を含浸させる方法など、液体を錠剤に保持させる公知の方法を採用することができる。好ましくは、素錠に精油を滴下する方法、素錠に精油を噴霧する方法、素錠に精油を含浸する方法である。   The sodium alginate-containing tablet (plain tablet) has good compatibility with the essential oil. By impregnating the essential oil into the plain tablet, the essential oil does not float and a tablet in which the essential oil is stably retained can be obtained. As a method of soaking essential oil, impregnating essential oil into uncoated tablets, spraying essential oil onto uncoated tablets, impregnating essential oil into uncoated tablets, impregnating uncompressed tablets and essential oil with a combination of reduced pressure and increased pressure A known method for holding a liquid in a tablet, such as a method or a method of impregnating at least the inner surface of a hollow expanded puffed tablet with essential oil, can be employed. Preferably, the essential oil is dropped into the uncoated tablet, the essential oil is sprayed onto the uncoated tablet, and the essential oil is impregnated into the uncoated tablet.

精油としては、パチュリー油、アニス油、サイプレス油、シダーウッド油、ショウノウ油、ジュニパー油、タイム油、ヒソップ油、ベルガモット油、ユーカリ油、安息香油、乳香油、ターペンタイン油、パイン油、セージ油、オレガノ油、カミルレ油、クラリセージ油、シナモン油、ゼラニウム油、バラ油、マージョラム油、ラベンダー油、没薬油などが挙げられ、これらのうち1種単独で又は2種以上組み合わせて使用することができる。好ましくはパチュリー油、ジャスミン油、サンダルウッド油、バジル油、メリッサ油、ジュニパー油、ラベンダー油、クローブ油である。特にパチュリー油はアルギン酸ナトリウムに保持された場合に安定性に優れる。また、パチュリー油は排便に効果のあることが知られているためアルギン酸ナトリウムの有する便通作用を増強する。さらに本発明者はパチュリー油がアルギン酸ナトリウムによるお腹のはりを抑制することを確認しており、その点でもパチュリー油は好ましい。また、精油の配合量は素錠中のアルギン酸ナトリウム100重量部に対し、通常0.01〜30重量部、好ましくは1〜5重量部である。
なお、素錠には精油の他の成分を添加することもでき、例えば、精油以外の香料、着色料、賦形剤、滑沢剤、結合剤、崩壊剤などの食品組成物、医薬組成物で使用されている添加物が挙げられる。素錠にこれら他の成分を添加し、常法により食品組成物、医薬組成物を製造することができる。また、素錠(精油をしみこませられた素錠も含む)は必要に応じて、コーティング錠(例えば、圧縮コーティング錠、膠衣錠、糖衣錠、フィルムコーティング錠など)とすることも可能である。コーティングの方法は常法により可能であり、コーティングのための成分(例えば、エチルセルロース、カゼイン、メチルセルロース、ヒドロキシエチルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルメチルセルロースフタレート、メタアクリル酸コポリマー、酢酸フタル酸セルロース、セラック、ゼラチン、アラビアゴム末、白糖、白ロウ、カルナウバロウなど)も公知のものを広く採用できる。
Essential oils include patchouli oil, anise oil, cypress oil, cedarwood oil, camphor oil, juniper oil, thyme oil, hyssop oil, bergamot oil, eucalyptus oil, benzoic oil, dairy oil, turpentine oil, pine oil, sage oil, Examples include oregano oil, chamomile oil, clary sage oil, cinnamon oil, geranium oil, rose oil, marjoram oil, lavender oil, and pilling oil. Among these, one kind can be used alone, or two or more kinds can be used in combination. Patchouli oil, jasmine oil, sandalwood oil, basil oil, melissa oil, juniper oil, lavender oil and clove oil are preferred. Patchouli oil in particular has excellent stability when held in sodium alginate. Patchouli oil is known to have an effect on defecation and therefore enhances the bowel movement of sodium alginate. Furthermore, the present inventor has confirmed that patchouli oil suppresses stomach belly caused by sodium alginate, and patchouli oil is also preferable in this respect. Moreover, the compounding quantity of essential oil is 0.01-30 weight part normally with respect to 100 weight part of sodium alginate in an uncoated tablet, Preferably it is 1-5 weight part.
In addition, other components of the essential oil can be added to the uncoated tablet, for example, a food composition such as a fragrance other than the essential oil, a coloring agent, an excipient, a lubricant, a binder, a disintegrant, and a pharmaceutical composition. And additives used in the above. A food composition and a pharmaceutical composition can be produced by a conventional method by adding these other components to the uncoated tablet. In addition, uncoated tablets (including uncoated tablets impregnated with essential oils) can be made into coated tablets (for example, compression-coated tablets, glue-coated tablets, sugar-coated tablets, film-coated tablets, etc.) as necessary. The coating method can be performed by a conventional method. Components for coating (for example, ethylcellulose, casein, methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose phthalate, methacrylic acid copolymer, cellulose acetate phthalate, shellac, gelatin Gum arabic powder, white sugar, white wax, carnauba wax, etc.) can be widely used.

本発明の錠剤及び組成物の摂取量は、摂取する人の年齢、体重、性別、摂取の目的、体調等に応じて適宜決定でき、特に限定されるものではないが、通常、アルギン酸ナトリウムの摂取量が1日成人1人当たり、0.01〜4g程度、好ましくは1〜3g程度となるような量を、1日に1回又は数回に分けて摂取することができる。   The intake of the tablet and composition of the present invention can be appropriately determined according to the age, weight, sex, purpose of intake, physical condition, etc. of the person who takes it, and is not particularly limited, but is usually intake of sodium alginate The amount can be taken once or several times a day so that the amount is about 0.01 to 4 g, preferably about 1 to 3 g per adult per day.

本発明は、直接粉末圧縮によりアルギン酸ナトリウムを錠剤化できるため、アルギン酸ナトリウムのみの錠剤を調製することができる。その結果、単位量あたりの食物繊維量に優れた錠剤を得ることができる。また、他の錠剤成型法と比較して、工程数が少ない点や高温を必要としない点で有利である。さらに、本発明の錠剤は精油との相性が良く、油浮きが抑制され、精油が安定的に錠剤に保持される。   In the present invention, since sodium alginate can be tableted by direct powder compression, tablets containing only sodium alginate can be prepared. As a result, a tablet excellent in the amount of dietary fiber per unit amount can be obtained. Further, it is advantageous in that the number of steps is small and a high temperature is not required as compared with other tablet molding methods. Furthermore, the tablet of the present invention has good compatibility with the essential oil, the oil floating is suppressed, and the essential oil is stably held in the tablet.

以下、本発明を実施例及び比較例を用いて、より詳細に説明するが、本発明はこれらに限定されるものではない。   EXAMPLES Hereinafter, although this invention is demonstrated in detail using an Example and a comparative example, this invention is not limited to these.

実施例1
1kgのアルギン酸ナトリウム粉末(平均粒子径80μm、キミカアルギン、株式会社キミカ製)を単発打錠機(菊水製作所製)にて打錠圧2トン/cmで打錠した。500mg/個の錠剤(円型)が得られた。
この錠剤を指でつまんでも崩壊することなく、また 、歯でも噛み砕けない程度に硬く、チャック袋で携帯し通常の生活を行っても割れ、ひび、欠け等も確認されず、さらに、1ヶ月チャック袋で保存しても、割れ、ひび、欠け等が無かったことから、実用に際して十分な硬度及び保形性を有していた。
また、打錠機のきね及びうすへのアルギン酸ナトリウム粉末の付着はほとんどなく、量産可能なレベルであった。
Example 1
1 kg of sodium alginate powder (average particle size 80 μm, Kimika Argin, manufactured by Kimika Co., Ltd.) was tableted with a single tableting machine (manufactured by Kikusui Seisakusho) at a tableting pressure of 2 ton / cm 2 . 500 mg / piece tablets (circular) were obtained.
This tablet does not disintegrate even if it is pinched with a finger, and it is hard enough not to be chewed by teeth, and it is not confirmed cracking, cracking, chipping, etc. even if it is carried in a normal bag and carried through a normal life. Even when stored in a zipper bag, there was no cracking, cracking, chipping, etc., and thus it had sufficient hardness and shape retention in practical use.
Moreover, there was almost no adhesion of the sodium alginate powder to the tablet and thin of a tableting machine, and it was a level which can be mass produced.

実施例2
実施例1で得られた錠剤に1錠当たり26mgのパチュリミントオイル(稲畑香料株式会社製)を滴下し1〜2時間静置し、浸透させた。
得られた錠剤を指でつまんでもオイルが指に付着することはなかった。また、この錠剤を常温で1ヶ月間チャック付きビニール袋中で保存した後、オイル量を測定(錠剤重量を電子天秤(ザルトリウス株式会社製)にて測定し、重量変化をみた)したところ、ほとんど変化しておらず、精油の保持が確認された。
また 、歯でも噛み砕けない程度に硬く、チャック袋で携帯し通常の生活を行っても割れ、ひび、欠け等も確認されず、さらに、1ヶ月チャック袋で保存しても、割れ、ひび、欠け等が無かったことから、実用に際して十分な硬度及び保形性を有していた。
Example 2
26 mg of patchouli mint oil (manufactured by Inabata Fragrance Co., Ltd.) was added dropwise to the tablet obtained in Example 1 and allowed to stand for 1 to 2 hours for permeation.
Even when the obtained tablet was pinched with a finger, the oil did not adhere to the finger. In addition, after storing this tablet in a plastic bag with a chuck at room temperature for one month, the amount of oil was measured (the weight of the tablet was measured with an electronic balance (manufactured by Sartorius Co., Ltd., and the change in weight was observed). There was no change, and the retention of essential oil was confirmed.
Also, it is hard enough not to be chewed by teeth, and it is not confirmed cracking, cracking, chipping, etc. even if it is carried in a chuck bag and carrying out normal life, and even if it is stored in a chuck bag for 1 month, it is cracked, cracked, Since there was no chipping, it had sufficient hardness and shape retention in practical use.

比較例1
アルギン酸ナトリウム粉末に代えてソルビトール(賦形剤、平均粒子径120μm)を使用し、実施例1と同じ条件で打錠し、得られた錠剤に実施例2と同じ条件でパチュリミントオイルを滴下した。
打錠により一応、成型できたが、表面は粘性を有し、打錠機のきね及びうすにソルビトールが付着しスティッキングを生じており、打錠毎にきね及びうすの清掃が必要となり、量産性がよくなかった。また、オイルを滴下された錠剤は、3時間後及び24時間後も表面にオイル分が浮いており、指でつまむとベタベタしていた。この錠剤を常温でチャック付きビニール袋中に保存し、3日後に観察すると錠剤が袋に付着した。
Comparative Example 1
Instead of sodium alginate powder, sorbitol (excipient, average particle size 120 μm) was used and tableted under the same conditions as in Example 1, and patchouli mint oil was added dropwise to the obtained tablets under the same conditions as in Example 2. .
Although it was able to be molded once by tableting, the surface has viscosity, sorbitol adheres to the kneading and thinning of the tableting machine, and sticking occurs. Mass production was not good. In addition, the oil-dropped tablet had oil on the surface after 3 hours and 24 hours, and was sticky when pinched with a finger. When this tablet was stored in a plastic bag with a chuck at room temperature and observed after 3 days, the tablet adhered to the bag.

比較例2
651gのアルギン酸ナトリウム、35gのパチュリミントオイル及び14gショ糖脂肪酸エステル(滑沢剤、平均粒子径120μm、DKエステルF−20W、第一製薬工業株式会社製)を混合した。この混合物を実施例1と同条件で打錠したところ、混合物の粉が非常にさらさらであり、錠剤として成型できなかった。
Comparative Example 2
651 g sodium alginate, 35 g patchouli mint oil and 14 g sucrose fatty acid ester (lubricant, average particle size 120 μm, DK ester F-20W, manufactured by Daiichi Pharmaceutical Co., Ltd.) were mixed. When this mixture was tableted under the same conditions as in Example 1, the powder of the mixture was very smooth and could not be molded as a tablet.

比較例3
38gのアルギン酸ナトリウム及び2gのパチュリミントオイルを混合した。混合物の粉は流動性が悪かったため、安息角を測定(三輪式円筒回転法安息角測定器(筒井理化学器械株式会社製))したところ65度であった。安息角が45度を超えると粉の流動性が悪くなり、打錠機への供給がスムーズに行われない。このため打錠機による量産は困難であった。
Comparative Example 3
38 g sodium alginate and 2 g patchouli mint oil were mixed. Since the powder of the mixture was poor in fluidity, the angle of repose was measured (three-wheeled cylinder rotation method angle of repose measuring instrument (manufactured by Tsutsui Riken Kikai Co., Ltd.)) and found to be 65 degrees. When the angle of repose exceeds 45 degrees, the fluidity of the powder is deteriorated and the supply to the tableting machine is not performed smoothly. For this reason, mass production with a tableting machine has been difficult.

本発明は食物繊維錠剤、食物繊維含有組成物の分野で有用である。   The present invention is useful in the fields of dietary fiber tablets and dietary fiber-containing compositions.

Claims (4)

アルギン酸ナトリウム粉末を打錠して得られる錠剤に精油をしみこませることを特徴とするアルギン酸ナトリウム含有錠剤の製造方法。 A method for producing a sodium alginate-containing tablet, comprising impregnating essential oil into a tablet obtained by tableting sodium alginate powder. 精油がパチュリー油、ジャスミン油、サンダルウッド油、バジル油、メリッサ油、ジュニパー油、ラベンダー油及びクローブ油からなる群から選択される少なくとも1種である請求項1に記載の製造方法。 The production method according to claim 1, wherein the essential oil is at least one selected from the group consisting of patchouli oil, jasmine oil, sandalwood oil, basil oil, melissa oil, juniper oil, lavender oil and clove oil. 精油配合量がアルギン酸ナトリウム100重量部に対し0.01〜30重量部である、請求項1又は2に記載の製造方法。 The manufacturing method of Claim 1 or 2 whose essential oil compounding quantity is 0.01-30 weight part with respect to 100 weight part of sodium alginate. 請求項1〜3のいずれかの製造方法により得られるアルギン酸ナトリウム含有錠剤。 The sodium alginate containing tablet obtained by the manufacturing method in any one of Claims 1-3.
JP2005100266A 2005-03-30 2005-03-30 Method for producing sodium alginate-containing tablet and tablet obtained by the production method Expired - Fee Related JP4873877B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2005100266A JP4873877B2 (en) 2005-03-30 2005-03-30 Method for producing sodium alginate-containing tablet and tablet obtained by the production method
PCT/JP2006/306762 WO2006106889A1 (en) 2005-03-30 2006-03-30 Methods of producing sodium alginate-containing tablet and tablets obtained by the production methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005100266A JP4873877B2 (en) 2005-03-30 2005-03-30 Method for producing sodium alginate-containing tablet and tablet obtained by the production method

Publications (2)

Publication Number Publication Date
JP2006273826A JP2006273826A (en) 2006-10-12
JP4873877B2 true JP4873877B2 (en) 2012-02-08

Family

ID=37073444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005100266A Expired - Fee Related JP4873877B2 (en) 2005-03-30 2005-03-30 Method for producing sodium alginate-containing tablet and tablet obtained by the production method

Country Status (2)

Country Link
JP (1) JP4873877B2 (en)
WO (1) WO2006106889A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013169146A (en) * 2012-02-17 2013-09-02 Kabaya Shokuhin Kk New refreshing confectionery and method for producing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2521463B2 (en) * 1987-03-16 1996-08-07 藤本製薬株式会社 Dilazep hydrochloride sustained release tablets
EP0484106A1 (en) * 1990-11-01 1992-05-06 Merck & Co. Inc. Controlled release formulations
JPH05236837A (en) * 1992-02-28 1993-09-17 Mitsubishi Materials Corp Essential oil-based deodorant for treating excreta for pet-toilet
JP4324252B2 (en) * 1996-07-26 2009-09-02 エステー株式会社 Insecticide for fiber pests and method
PL195031B1 (en) * 1997-04-30 2007-08-31 Reckitt Benckiser Healthcare An aqueous pourable liquid composition comprising a high concentration of sodium alginate and an alkali metal bicarbonate
IL127396A0 (en) * 1998-12-03 1999-10-28 Univ Ben Gurion A sustained-release polysaccharide-protein water insoluble bead and a process for preparing the same
JP2001220304A (en) * 2000-02-09 2001-08-14 Kao Corp Antibacterial agent for mold with offensive odor
TWI268138B (en) * 2000-05-11 2006-12-11 Kanebo Seiyaku Ltd Composition containing peptide and electrolyte excretion enhancing substance, and food containing the same

Also Published As

Publication number Publication date
JP2006273826A (en) 2006-10-12
WO2006106889A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
FI109086B (en) Process for preparing a tablet of increased strength
JP4890260B2 (en) Film-forming starch composition
DE59206345D1 (en) Process for the production of mechanically stable, well disintegrating compressed materials from small shaped articles containing active ingredients
FR2618673A1 (en) DRUG FORMULA WITH CONTROLLED RELEASE
JPS5841815A (en) Manufacture of dosage shape
JP4059908B2 (en) Functional chews and method for producing the same
WO2005117921A1 (en) Oral form of administration containing probiotic bacteria
JP2011088838A (en) Manufacturing method of tablet containing arginine and carnitine
JPH06206833A (en) Pharmaceutical drug
JP4873877B2 (en) Method for producing sodium alginate-containing tablet and tablet obtained by the production method
JPS5945850A (en) Compression solidified waer soluble sweetener tablet
JP6589979B2 (en) Tablet composition and method for improving disintegration and dissolution of tablet composition
JPS648605B2 (en)
WO2018159673A1 (en) Erythritol granules and method for producing same, method for producing tablets using same, and tablets
JP6654012B2 (en) Tablets containing chitosan and / or chitin
JP3957932B2 (en) Water-soluble coating composition for food
WO2001007016A1 (en) Process for the production of soft capsules and coating materials and lubricants to be used therefor
JP2011006377A (en) Orally disintegrable tablet which contains precipitated calcium carbonate as active ingredient
JP2007302570A (en) Sustained release preparation containing thioctic acid
JP2008280251A (en) Multilayered tablet and method for producing the same
JPS5879917A (en) Molding of glycine tablet
JP7475393B2 (en) Tablet Composition
KR102240935B1 (en) Techniques for improving the disintegration and storage stability of tablet containing fingerroot extract as an active ingredient
JP4388607B2 (en) Casein hard capsule and method for producing the same
JP6100939B2 (en) Method for improving hygroscopicity / fluidity of solid preparation for internal use, solid preparation for internal use with improved hygroscopicity / flowability, and method for producing the solid preparation for internal use

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110726

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110913

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111101

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111122

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141202

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4873877

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees